Department of Frontier Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8677, Japan.
Esophagus. 2021 Oct;18(4):844-850. doi: 10.1007/s10388-021-00851-z. Epub 2021 May 21.
Intravoxel incoherent motion MRI (IVIM-MRI) can quantify micro-perfusion at the capillary level in the tissue. The purpose of this study is to measure tumor perfusion using IVIM-MRI, and evaluate its value as a biomarker to predict prognosis in esophageal squamous cell carcinoma (ESCC) patients.
109 ESCC patients (93 men and 16 women; median age: 72) who underwent IVIM-MRI prior to treatment between February 2018 and August 2020 were retrospectively investigated. Both mean apparent diffusion coefficient (ADC) value and mean perfusion-related parameter (PP) value of the primary tumor were measured using three b values of 0, 400, and 1000 s/mm based on the IVIM model. We analyzed associations of these parameters with clinical stage and disease-specific survival (DSS).
Lower ADC and PP values of the tumor were significantly associated with the higher clinical T stage (p < 0.0001, p < 0.0001, respectively). In Kaplan-Meier analyses, patients with lower PP value tumors (< 18.94, median) had significantly worse DSS (p < 0.0001), while tumor ADC value did not show a significant correlation with DSS. In a multivariate analysis, PP value of the tumor was an independent prognostic factor for DSS (p = 0.0027).
Quantification of tumor perfusion using IVIM-MRI can be a non-invasive prognostic biomarker of ESCC, reflecting clinical stage and survival.
体素内不相干运动 MRI(IVIM-MRI)可定量组织中毛细血管水平的微灌注。本研究旨在使用 IVIM-MRI 测量肿瘤灌注,并评估其作为预测食管鳞状细胞癌(ESCC)患者预后的生物标志物的价值。
回顾性分析了 2018 年 2 月至 2020 年 8 月期间 109 例接受治疗前 IVIM-MRI 的 ESCC 患者(男 93 例,女 16 例;中位年龄:72 岁)。基于 IVIM 模型,使用 0、400 和 1000 s/mm 三个 b 值测量原发肿瘤的平均表观扩散系数(ADC)值和平均灌注相关参数(PP)值。分析这些参数与临床分期和疾病特异性生存(DSS)的相关性。
肿瘤 ADC 值和 PP 值较低与较高的临床 T 分期显著相关(p<0.0001,p<0.0001)。Kaplan-Meier 分析显示,PP 值较低的肿瘤患者(<18.94,中位值)的 DSS 显著较差(p<0.0001),而肿瘤 ADC 值与 DSS 无显著相关性。多变量分析显示,肿瘤的 PP 值是 DSS 的独立预后因素(p=0.0027)。
使用 IVIM-MRI 定量肿瘤灌注可以作为 ESCC 的一种非侵入性预后生物标志物,反映临床分期和生存。